1752-153X-2-10 1752-153X Preliminary communication <p>Study on the effects of nitrilotriproprionic acid and 4,5-dihydroxy-1,3-benzene disulphonate on the fractionation of beryllium in human serum using graphite furnace atomic absorption spectrometry</p> Stephan H Chadi chadi.stephan@umontreal.ca Fournier Michel michel.fournier@iaf.inrs.ca Brousseau Pauline pauline.brousseau@iaf.inrs.ca Sauvé Sébastien sebastien.sauve@umontreal.ca

Department of Chemistry, Université de Montréal, PO 6128, Station Centre-Ville, Montréal, QC, H3C 3J7, Canada

INRS-Institut Armand-Frappier, 245 Hymus, Pointe-Claire, QC, H9R 3G6, Canada

Chemistry Central Journal 1752-153X 2008 2 1 10 http://journal.chemistrycentral.com/content/2/1/10 18479524 10.1186/1752-153X-2-10 13 2 2008 14 5 2008 14 5 2008 2008 Stephan et al This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Occupational exposure to beryllium may cause Chronic Beryllium Disease (CBD), a lung disorder initiated by an electrostatic interaction with the MHC class II human leukocyte antigen (HLA). Molecular studies have found a significant correlation between the electrostatic potential at the HLA-DP surface and disease susceptibility. CBD can therefore be treated by chelation therapy. In this work, we studied the effect of two complexing agents, nitrilotriproprionic acid (NTP) and 4,5-dihydroxy-1,3-benzene disulphonate (Tiron), on the fractionation of beryllium in human serum analysed by graphite furnace atomic absorption spectrometry (GFAAS).

Results

We found the average serum beryllium concentration of fourteen non-exposed individuals to be 0.53 (± 0.14) μg l-1, with 21 (± 3)% of the beryllium mass bound to the low molecular weight fraction (LMW), and 79 (± 3)% bound to the high molecular weight fraction (HMW). The addition of Tiron increased the beryllium mass in the HMW fraction, while NTP was not seen to have any influence on the fractionation of beryllium between the two fractions. NTP was, however, shown to complex 94.5% of the Be mass in the LMW fraction. The beryllium GFAAS detection limit, calculated as three times the standard deviation of 10 replicates of the lowest standard (0.05 μg L-1), was 6.0 (± 0.2) ng L-1.

Conclusion

The concentration of beryllium or its fractionation in human serum was not affected by sex or smoking habit. On average, three quarters of the beryllium in serum were found in the HMW fraction. Of the two ligands tested, only Tiron was effective in mobilising beryllium under physiological conditions, thus increasing the Be content in the HMW fraction.

Background

Beryllium, the first of the alkaline earth metals, is naturally found in mineral rocks, coal, soil, and volcanic dust 1. Beryllium ore is mined and purified for its use in nuclear reactors, weapons, aircraft and space vehicle structures, x-ray machines, as well as telecommunication and high-tech devices 2. Occupational exposure to beryllium may cause Chronic Beryllium Disease (CBD), a lung disorder characterised by a granulomatous inflammation initiated by an electrostatic interaction with the MHC class II human leukocyte antigen (HLA) 34. Molecular epidemiological studies have shown that interaction between beryllium and specific HLA-DP alleles is a factor in disease susceptibility 5. Furthermore, molecular modelling has been used to investigate a potential mechanistic basis for these observations. A significant correlation has been found between the risk of chronic beryllium disease associated with specific alleles, and the predicted electrostatic surface potential, suggesting that the alleles associated with the most negatively charged proteins carry the greatest risk of beryllium sensitisation and disease 6.

At present, CBD can be treated but not cured. Adrenocortical steroids such as prednisone, prednisolone and dexamethasone act to reduce the inflammation and immune response to beryllium but cannot eliminate beryllium from organs or tissues, a key factor in stopping CBD 7. Chelation therapy 189 or metal encapsulation 10 can eventually provide an alternative or adjunctive treatment to accelerate beryllium clearance from organs and tissues. In this work, we looked at the natural distribution of beryllium in serum and investigated the effect of two sequestering agents, nitrilotriproprionic acid (NTP) and 4,5-dihydroxy-1,3-benzene disulphonate (Tiron) (Figure 1), on the distribution of beryllium. We used a mobilisation index (MI) 111213 to represent the relative ability of a complexing agent to compete for the metal of interest and mobilise it under physiological conditions. The MI is defined as:

<p>Figure 1</p>

Chemical structures of nitrilotripropionic acid (NTP) and 4,5-dihydroxy-1,3-benzene disulphonate (Tiron)

Chemical structures of nitrilotripropionic acid (NTP) and 4,5-dihydroxy-1,3-benzene disulphonate (Tiron).

M I = ( t o t a l c o n c e n t r a t i o n o f l o w m o l e c u l a r w e i g h t b e r y l l i u m i n t h e p r e s e n c e o f t h e c o m p l e x i n g a g e n t ) ( t o t a l c o n c e n t r a t i o n o f l o w m o l e c u l a r w e i g h t b e r y l l i u m i n t h e a b s e n c e o f t h e c o m p l e x i n g a g e n t ) MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacPC6xNi=xI8qiVKYPFjYdHaVhbbf9v8qqaqFr0xc9vqFj0dXdbba91qpepeI8k8fiI+fsY=rqGqVepae9pg0db9vqaiVgFr0xfr=xfr=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@0E9E@

Nitrilotripropionic acid was selected because of its physico-chemical properties: it complexes beryllium in a tetrahedral complex [Be(NTP)]- where the beryllium cation lies at the centre of a slightly distorted tetrahedron of C3υ symmetry, with a longer Be-N bond and three equal Be-O bonds 14. Tiron is a hydrophilic chelator and was selected because of its reported efficiency in mobilising beryllium 1516, restoring the altered biochemical parameters 17 and improving the altered hepatorenal biochemistry and ultramorphology in different rat tissues and organs 18.

Beryllium, like any other metal ions in serum, can be fractionated into four distinct groups: rigidly bound to metalloproteins; loosely bound to other types of proteins (labile equilibrium); complexed by the so-called low-molecular-weight fraction (LMW); and occurring as free (or hydrated) metal ions 12.

In this study, we looked first at the natural distribution of beryllium in serum and the influence of NTP and Tiron on this distribution. We focused on two operationally-defined fractions; the first fraction combines the Be rigidly and loosely bound to proteins, and is called the high molecular weight fraction (HMW); whilst the second fraction, that is the low molecular weight fraction (LMW), combines the Be complexed to the low molecular-weight fraction or that which occurs in its free ionic form. We separated the HMW and LMW fractions by ultrafiltration with Centricon centrifugal filter devices at a 10,000 nominal molecular weight limit (NMWL) cut-off. Beryllium quantification in serum and serum fractions was carried out using an optimised graphite furnace atomic absorption spectrometer (GF-AAS). The accuracy of the analytical method was tested using Seronorm samples (Seronorm trace elements whole blood level 2, STEWB; Ref # 201605; Lot # 0503109).

Results and discussion

Beryllium in serum

The average beryllium concentration in fourteen non-exposed individuals (9 females and 5 males; 9 non smokers and 5 smokers) found to be 0.53 (± 0.14) μg L-1. Neither sex nor smoking habit was shown to have a significant influence on the concentration of beryllium in serum (independent sample T-test, p > 0.05). The method detection limit, calculated as three times the standard deviation of 10 replicates of the lowest standard (0.05 μg L-1), was 6.0 (± 0.2) ng L-1. The accuracy of the method varied from 99 to 104% and was verified by analysing a control sample (STEWB level 2 certified blood material with a concentration of 5.9 (± 0.5) μg Be L-1).

Beryllium distribution in serum

On average, 21 (± 3)% of the beryllium mass was bound to the LMW fraction, with 79 (± 3)% bound to the HMW fraction (Table 1). Neither sex nor smoking habit was shown to have a significant influence on the distribution of beryllium between the LMW and the HMW fractions (independent sample T-test, p > 0.05). These findings agree with the work of Stiefel et al. 19 conducted on human and guinea pig blood. They reported that the corpuscular part of all samples contained from 2 to 10% of the total Be, the LMW fraction contained between 17 and 33%, with 60 to 73% of the total Be bound to the HMW fraction – or more specifically bound to the pre-albumins and the γ-globulins fractions. They also reported that the Be distribution between the two protein regions depends on the absolute concentration of Be in blood. At concentrations lower than 1 μg L-1, most of the Be mass (> 90%) was bound to the γ-globulins fraction, while at higher concentrations most of the Be mass was found bound to the pre-albumins fraction. This is very similar to the chemical speciation of aluminium in human serum, were almost all the Al mass in the HMW fractions was bound to transferrin belonging to the γ-globulins protein fractions 202122. Beryllium and aluminium have very similar chemical properties 1. In an attempt to better understand beryllium chemistry in human body fluids, Sutton and Burastero 23 have simulated the speciation of beryllium in plasma fluid (LMW fraction) and reported most of the beryllium at pH 7.4 to be aqueous BeCO3 (49.4%) and BeOH+ (39.9%). A reproduction of this speciation is presented in Figure 2, where in using the chemical equilibrium software Mineql+ 24 we show that adding citrate and oxalate, should complex most of the Al in the LMW human serum 2022252627. We obtained similar results and found that most of the beryllium at pH 7.4 is shown to exist as aqueous Be(OH)+ (60.5%), BeCO3 (27.4%) and Be(OH)2 (10.2%). Neither citrate nor oxalate influenced the speciation of beryllium at serum pH, although both ligands complexed beryllium at acidic pH with maxima of 16.2% (at pH = 3) and 9% (at pH = 5.5) for Be(oxalate) and Be(citrate) respectively.

<p>Figure 2</p>

Speciation of Be in the LMW of serum fluid ([Be] 5.8*10-5 mM; [Ca] 1.3 mM; [Cl] 108 mM; [CO3] 24 mM; [K] 4.2 mM; [Mg] 0.8 mM; [Na] 142 mM; [PO4] 2 mM; [SO4] 0.5 mM; [Cit] 0.1 mM; [Ox] 0.01 mM)

Speciation of Be in the LMW of serum fluid ([Be] 5.8*10-5 mM; [Ca] 1.3 mM; [Cl] 108 mM; [CO3] 24 mM; [K] 4.2 mM; [Mg] 0.8 mM; [Na] 142 mM; [PO4] 2 mM; [SO4] 0.5 mM; [Cit] 0.1 mM; [Ox] 0.01 mM).

 <p>Table 1</p>

Concentration and natural distribution of beryllium in the human serum of non-exposed individuals.

Sample

Sex

Smoking

Serum (μg L-1)

LMW (%)

HMW (%)

1

F

S

0.54 (0.08)

22 (2)

78 (3)

2

F

NS

0.46 (0.04)

24 (3)

76 (3)

3

F

S

0.47 (0.09)

19 (1)

81 (1)

4

F

NS

0.42 (0.05)

24 (2)

76 (2)

5

F

NS

0.49 (0.07)

21 (2)

79 (2)

6

M

NS

0.44 (0.02)

25 (3)

75 (3)

7

F

NS

0.45 (0.01)

25 (3)

75 (3)

8

F

NS

0.44 (0.01)

19 (1)

81 (1)

9

F

NS

0.46 (0.01)

24 (3)

76 (3)

10

M

NS

0.45 (0.01)

16 (3)

84 (3)

11

M

S

0.78 (0.03)

23 (4)

77 (4)

12

F

NS

0.69 (0.03)

21 (5)

79 (5)

13

M

S

0.45 (0.04)

20 (3

80 (3)

14

M

S

0.86 (0.01)

21 (3)

79 (3)

Mean

0.53 (0.14)

21 (3)

79 (3)

F = female; M = male; S = smoking; NS = non smoking

In an attempt to investigate the chelation effect of Tiron and NTP, as well as study their effect on the repartition of beryllium in human serum, dose-response experiments were conducted showing the influence of both complexing agents on the repartition of beryllium between the two serum fractions. We tested different equilibration times (2, 4 and 6 h), but found no differences for both ligands, suggesting that the exchange reactions rates are almost instantaneous and that equilibrium is reached within the 2 hour equilibration timeframe employed. This is similar to the Al-transferrin exchange reaction rate with desferrioxamine B (DFO) where the addition of DFO increased the amount of ultrafiltrable Al sharply up to 90% of the total plasma Al content 2829. Due to the similarity between Be and Al "hard ions", and DFO, NTP and Tiron "complexing agents with soft oxygen donors", we should expect almost instant exchange reaction rates for the Be-Tiron-HMW and Be-NTP-HMW systems, thus confirming that the 2-h equilibration time is more than enough for the exchange to occur.

In spiked and non-spiked samples (Figures 3 and 4), Tiron showed an increasing pattern of the beryllium mass in the HMW fraction. Such results contradict the general behaviour of complexing agents, which usually tend to increase the metal concentration in the LMW fraction 1213. In the spiked samples, the addition of Tiron increased the mass fraction of beryllium in the HMW from an average of 76 (± 4)%, reaching a maximum of 93 (± 2)% at 10-3 M. Conversely, the average concentration of beryllium in the LMW fraction decreased from 24 (± 4)% to 7 (± 2)%. This increase in the Be-HMW fraction becomes significant at 10-5 M (One-Way Anova, Fisher's LSD, with P < 0.05). We observed the same pattern in non-spiked samples. The HMW beryllium content increased from an average of 79 (± 3)% to 90 (± 4)% at 10-3 M, while the LMW beryllium content decreased from 20 (± 3)% to 10 (± 4)%. This change in the Be-HMW fraction is only significant at 10-3 M. These observations confirm that Tiron complexes Be under serum conditions and increases the beryllium content in the HMW fraction by generating a mobilisation index that decreases with increasing Tiron concentrations (Figure 5). Tiron complexes Be in a 2:1 ratio 3031, most probably generating a less charged complex that tends to be more soluble in the HMW fraction than in the hydrophilic LMW fraction. We suspect that such behaviour might increase the toxicity of beryllium, but several recent studies have shown that Tiron (with or without the aid of adjuvants) restored the altered biochemical physiological parameters and oxidative stress response in rats exposed to beryllium 151831.

<p>Figure 3</p>

Influence of Tiron on the repartition of beryllium between the HMW and the LMW fractions in three spiked individuals

Influence of Tiron on the repartition of beryllium between the HMW and the LMW fractions in three spiked individuals. * Significant difference calculated by One-Way Anova, Fisher's LSD.

 <p>Figure 4</p>

Influence of Tiron on the repartition of beryllium between the HMW and the LMW fractions in three non-spiked individuals

Influence of Tiron on the repartition of beryllium between the HMW and the LMW fractions in three non-spiked individuals. * Significant difference calculated by One-Way Anova, Fisher's LSD.

 <p>Figure 5</p>

Mobilisation Index (MI) of Be as a function of Tiron concentration

Mobilisation Index (MI) of Be as a function of Tiron concentration.

NTP did not show any significant influence on the beryllium partitioning either in spiked or non-spiked samples (Figures 6 and 7). In spiked samples, the HMW average beryllium fractionation did not change significantly (One-Way Anova, Fisher's LSD, with P < 0.05) with increasing NTP concentration. We obtained a stable pattern that varied from 76 (± 4)% for the control to 77 (± 5)% at 10-3 M. Similar observations were observed in non-spiked samples. The HMW average beryllium content pattern varied from 77 (± 5)% for the control to 80 (± 4)% at 10-3 M. Under physiological serum conditions, NTP did not influence the MW distribution of Be between the HMW and LMW fractions, but showed a capacity to complex most of the beryllium in the LMW, as shown by the chemical speciation simulations (Figure 8). At a concentration of 10-7 M, NTP was shown to complex 94.5% of the Be in the LWM followed by 3.4% and 1.1% of the Be occurring as Be(OH)+ and BeCO3, respectively. These results support earlier findings which suggest that NTP would be an ideal complexing agent for Be 14.

<p>Figure 6</p>

Influence of NTP on the repartition of beryllium between the HMW and the LMW fractions in three spiked individuals

Influence of NTP on the repartition of beryllium between the HMW and the LMW fractions in three spiked individuals. * Significant difference calculated by One-Way Anova, Fisher's LSD.

 <p>Figure 7</p>

Influence of NTP on the repartition of beryllium between the HMW and the LMW fractions in three non-spiked individuals

Influence of NTP on the repartition of beryllium between the HMW and the LMW fractions in three non-spiked individuals. * Significant difference calculated by One-Way Anova, Fisher's LSD.

 <p>Figure 8</p>

Influence of NTP on the speciation of Be in the LMW of serum fluid ([Be] 5.8*10-5 mM; [NTP] 10-4 mM; [Ca] 1.3 mM; [Cl] 108 mM; [CO3] 24 mM; [K] 4.2 mM; [Mg] 0.8 mM; [Na] 142 mM; [PO4] 2 mM; [SO4] 0.5 mM; [Cit] 0.1 mM; [Ox] 0.01 mM)

Influence of NTP on the speciation of Be in the LMW of serum fluid ([Be] 5.8*10-5 mM; [NTP] 10-4 mM; [Ca] 1.3 mM; [Cl] 108 mM; [CO3] 24 mM; [K] 4.2 mM; [Mg] 0.8 mM; [Na] 142 mM; [PO4] 2 mM; [SO4] 0.5 mM; [Cit] 0.1 mM; [Ox] 0.01 mM).

Conclusion

Neither sex nor smoking habit was shown to influence beryllium concentration or its fractionation in human serum. On average, three quarters of the beryllium in serum were found to be bind to the HMW fraction. Tiron, unlike NTP, showed a significant interaction with beryllium under physiological conditions by increasing the Be content in the HMW fraction – in contrast to that which is usually observed for standard complexing agents used in chelation therapy. The addition of NTP did not affect the MW distribution between the two fractions but was shown to complex most of the Be in the LMW fraction. Further work could employ anion exchange fast protein liquid chromatography (FPLC) coupled with electrospray tandem mass spectrometry (ES-MS-MS) or inductively coupled plasma mass spectrometry to confirm the nature of the ligands or proteins that complex Be in both serum fractions 20212227.

Experimental

Reagents

All of the reagents used were of analytical grade or better. Antifoam B silicone emulsion (J.T. Baker, NJ, USA), ammonium hydroxide (certified A.C.S. Plus, Fisher scientific, NJ, USA), ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) (Fluka chemika, Switzerland), Triton X-100 (Acros, NJ, USA), nitric acid (trace metal grade, Fisher Scientific, Ontario, Canada), beryllium plasma standard solution (Specpure, Alfa Aesar, MA, USA), nitrilotripropionic acid (NTP) (MP Biomedicals, Ohio, USA) and 4,5-dihydroxy-1,3-benzene disulphonate (Tiron) (Acros Organics, New Jersey, USA).

Solutions

Serum samples were diluted with a Nash reagent (NR) solution prepared weekly and containing 5% (v/v) nitric acid, 5% (v/v) of ammonium hydroxide, 0.2% (v/v) Triton X-100, 0.2% (v/v) antifoam B and 0.5% (w/v) of EDTA in distilled-deionised water. Solutions of NTP and Tiron were prepared at 10-1, 10-2, 10-3, 10-4 and 10-5 M by dissolving the appropriate mass in 2% (v/v) HNO3 aqueous solution. A 50 μg L-1 working Be (II) solution was prepared by dilution of the beryllium stock solution (1000 μg L-1) in 2% (v/v) HNO3. The Be standard solution was prepared daily by dilution of the working Be (II) solution with the Nash reagent to give a final concentration of 0.5 μg L-1.

Sample preparation

Blood from unexposed individuals was collected in BD vacutaine SST tubes (BD Franklin lakes, New Jersey, USA). Tubes were left at room temperature for 30 minutes to allow clot formation and then centrifuged at 500 g for 10 minutes. Supernatants of each individual were collected and recombined to ensure sample homogenisation. Each sample was divided into twelve 2.5 mL sub-samples in borosilicate disposable culture tubes, two served as controls, five were spiked with NTP and five were spiked with Tiron at concentrations ranging from 10-7 to 10-3 M. Sub-samples were left to equilibrate for two hours. A 2 mL aliquot of each sub-sample was transferred to a Centricon centrifugal device with ultracel YM-10 (10,000 MWCO) (Millipore Corporation, Ireland) and centrifuged at 4500 g for 90 minutes. The LMW and HMW fractions obtained were analysed for beryllium by graphite furnace atomic absorption spectrometry (GFAAS) after respective 2-fold and 5-fold dilutions with NR. The same experimental procedure was repeated on serum samples that were spiked with 1 μg L-1 of beryllium. We also measured the beryllium concentration in fourteen individuals and looked at the natural distribution of beryllium between the HMW and LMW fractions. Serum was diluted 5-fold with NR before GFAAS analysis.

Graphite furnace atomic absorption spectrometer

A Varian AA280Z Zeeman atomic absorption spectrometer, equipped with a Zeeman background correction, GTA 120 graphite tube atomiser and PSD 120 programmable sample dispenser was used for the atomic absorption measurement of beryllium at 234.9 nm with a spectral bandwidth of 1.0 nm. A beryllium hollow cathode lamp (Varian, Part No. 5610100500) was used as a light source operated at 5 mA. Pyrolytic graphite coated partitioned tubes (Varian partition tubes, Part No. 63-100012-00) were used for all experiments. High purity Argon (99.99%) was used as the carrier gas. A beryllium hollow cathode lamp (Varian, Part No. 5610100500) was used as a light source. Instrument control, sample results, signal graphics and data collection are controlled by the SpectrAA Worksheet software for the Windows® XP operating system. Peak area values were used for beryllium signal and background (BG) measurements. The instrumental conditions and the furnace program are listed in Table 2.

<p>Table 2</p>

The furnace programme for the determination of beryllium in serum.

Step

Temp (°C)

Time (s)

Argon flow rate (L min-1)

Drying

85

5

0.3

Drying

95

30

0.3

Drying

120

20

0.3

Pre-pyrolysis

450

22

0.3

Pyrolysis

1000

17

0.3

Atomizing

2900

3

0

Cleaning

2900

2

0.3

Chemical Speciation

For the chemical speciation calculations, we used MINEQL+ (version 4.5 for Windows – Environmental Research Software, Hallowell, ME), a chemical equilibrium modelling system that can be used to perform calculations at low temperatures (0–50°C) and low to moderate ionic strength (< 0.5 M). MINEQL+ operates over three steps: creation of a system by selecting chemical components from a menu with the possibility of adding new ligands, then scanning the thermodynamic database and finally running the calculations with actual measured concentrations included. The output data module yields the activity for each species of each component. Our chemical speciation calculations were made assuming the following parameters (unless specified otherwise): T = 37°C (fixed), ionic strength: I = 0.01 M (fixed), Log pCO2 = -3.5 (open atmosphere). Different chemical equilibrium software should yield similar results when the same stability constants are used. The following input data were added to the MINEQL+ thermodynamic database; Log KBe-Ox = 3.47, Log KBe-(Ox)2 = 5.24, Log KBe-NTP = 13.94, Log KH3-NTP = 11.54, Log KH2-NTP -1 = 10.31 and Log KH-NTP -2 = 7.59.

Statistical analysis

Statistical analysis was performed with SPSS (version 13 for Windows, SPSS Inc, Chicago, IL) using independent sample T-tests to monitor significant differences among groups. We also used One-Way ANOVA tests with Fisher's LSD (least significant difference) to make pair wise comparisons as a way of monitoring significant changes within a group.

Authors' contributions

All authors contributed to the experimental design. CHS carried out nearly all of the laboratory work, the initial interpretation of the data and the initial write-up. PB and MF contributed their expertise especially with the biological work, and SS focused on the analytical chemistry.

Acknowledgements

We thank the Natural Sciences and Engineering Research Council of Canada and the Institut de Recherche Robert-Sauvé en Santé et en Sécurité du Travail for financial support.

 <p>Beryllium Coordination Chemistry</p> Wong CY Woollins JD Coordination Chemistry Reviews 1994 130 243 273 10.1016/0010-8545(94)80006-5 <p>Introduction to the Conference on Beryllium-Related Diseases</p> Jameson CW Environmental Health Perspectives 1996 104 935 936 1469677 8933037 <p>Identification of pathogenic T cells in patients with beryllium-induced lung disease</p> Fontenot AP Falta MT Freed BM Newman LS Kotzin BL Journal of Immunology 1999 163 1019 1026 <p>Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69</p> Amicosante M Sanarico N Berretta F Arroyo J Lombardi G Lechler R Colizzi V Saltini C Human Immunology 2001 62 686 693 10.1016/S0198-8859(01)00261-0 11423174 <p>Detailed analysis of the effects of Glu/Lys beta 69 human leukocyte antigen-DP polymorphism on peptide-binding specificity</p> Berretta F Butler RH Diaz G Sanarico N Arroyo J Fraziano M Aichinger G Wucherpfennig KW Colizzi V Saltini C Amicosante M Tissue Antigens 2003 62 459 471 10.1046/j.1399-0039.2003.00131.x 14617029 <p>HLA-DPB1 and chronic beryllium disease: A HuGE review</p> McCanlies EC Kreiss K Andrew M Weston A Am J Epidemiol 2003 157 388 398 10.1093/aje/kwg001 12615603 <p>Chronic beryllium disease: Diagnosis and management</p> Rossman MD Environmental Health Perspectives 1996 104 945 947 1469698 8933039 10.2307/3433015 <p>Effects of Meso-2,3-Dimercaptosuccinic Acid Or 2,3-Dimercaptopropane 1-Sulfonate on Beryllium-Induced Biochemical-Alterations and Metal Concentration in Male-Rats</p> Flora SJS Mathur S Mathur R Toxicology 1995 95 167 175 10.1016/0300-483X(94)02903-8 7825183 Seiler HG Sigel H Sigel A Handbook on toxicity of inorganic compounds New York, Marcel Dekker 1988 753 758 <p>Metal-Binding by Amino-Acids - Preparation and Crystal-Structures of Lithium, Sodium, and Potassium Hydrogen Bis-L-Pyroglutamate</p> Kumberger O Riede J Schmidbaur H Chemische Berichte-Recueil 1992 125 1829 1834 10.1002/cber.19921250808 <p>Metal-Ion Speciation in Blood-Plasma As A Tool for Elucidating the In-Vivo Behavior of Radiopharmaceuticals Containing Sm-153 and Ho-166</p> Jarvis NV Wagener JM Jackson GE Journal of the Chemical Society-Dalton Transactions 1995 1411 1415 10.1039/dt9950001411 <p>Computer simulation of chelation therapy Plasma mobilizing index as a replacement for effective stability constant</p> May PM Williams DR FEBS Letters 1977 78 134 138 10.1016/0014-5793(77)80290-1 872932 <p>Metal binding by pharmaceuticals. Part 5. Interaction of Cd(II), Ni(II) and Pb(II) with the intracellular hydrolysis products of the anti-tumour agent ICRF 159 and its inactive homologue ICRF 192</p> Peter MM Michael JW David RW Andrew MC Inflammation Research 1984 V15 448 453 <p>Nitrilotripropionic Acid (Ntp) and Other Polyamino Carboxylic-Acids As Sequestering Agents for Beryllium(Ii) - X-Ray Crystal-Structure of Sodium (Nitrilotripropionato)Beryllate(Ii) Trihydrate, Na[Be(Ntp)]Center-Dot-3H(2)O</p> Chinea E Dominguez S Mederos A Brito F Arrieta JM Sanchez A Germain G Inorg Chem 1995 34 1579 1587 10.1021/ic00110a041 <p>Influence of tocopherol, propolis and piperine on therapeutic potential of tiferron against beryllium induced toxic manifestations</p> Nirala S Bhadauria M Mathur R Mathur A Journal of Applied Toxicology 2008 28 44 54 10.1002/jat.1250 17429802 <p>Beryllium-induced toxicity and its prevention by treatment with chelating agents</p> Sharma P Johri S Shukla S Journal of Applied Toxicology 2000 20 313 318 10.1002/1099-1263(200007/08)20:4<313::AID-JAT660>3.0.CO;2-J 10942906 <p>Mobilization and Distribution of Beryllium Over the Course of Chelation-Therapy with Some Polyaminocarboxylic Acids in the Rat</p> Mathur S Flora SJS Mathur R Dasgupta S Human & Experimental Toxicology 1993 12 19 24 8094965 <p>Amelioration of beryllium induced alterations in hepatorenal biochemistry and ultramorphology by co-administration of tiferron and adjuvants</p> Nirala S Bhadauria M Mathur R Mathur A Journal of Biomedical Science 2007 14 331 345 10.1007/s11373-007-9147-5 17278010 <p>Analysis of trace elements distributed in blood</p> Steifel T Schulze K Tolg G Fresenius' Journal of Analytical Chemistry 1980 300 189 196 10.1007/BF00488332 <p>The chemical speciation of aluminium in human serum</p> Sanz-Medel A Soldado Cabezuelo AB Milacic R Polak TB Coordination Chemistry Reviews 2002 228 373 383 10.1016/S0010-8545(02)00085-1 <p>Quantitative studies of aluminium binding species in human uremic serum by fast protein liquid chromatography coupled with electrothermal atomic absorption spectrometry</p> Soldado Cabezuelo AB Gonzalez EB Sanz-Medel A Analyst 1997 122 573 577 10.1039/a608258k 9282403 <p>Speciation of basal aluminium in human serum by fast protein liquid chromatography with inductively coupled plasma mass spectrometric detection</p> Soldado Cabezuelo AB Bayon MM Gonzalez EB Alonso JI Sanz-Medel A Analyst 1998 123 865 869 10.1039/a707669j 9709479 <p>Beryllium Chemical Speciation in Elemental Human Biological Fluids</p> Sutton M Burastero SR Chem Res Toxicol 2003 16 1145 1154 10.1021/tx0256477 12971803 <p>MINEQL+</p> Schecher WD McAvoy DC Hallowell, ME., Environmental Research Software 2003 12757562 <p>Citrate As the Main Small-Molecule Binding Al3+ in Serum</p> Ohman LO Martin RB Clinical Chemistry 1994 40 598 601 8149616 <p>Possibilities for speciation of Al-citrate and other negatively charged Al complexes by anion-exchange FPLC-ICP-AES</p> Bantan T Milacic R Pihlar B Talanta 1998 46 227 235 10.1016/S0039-9140(97)00282-8 <p>Quantitative determination of trace amounts of Al-citrate by anion-exchange FPLC-ETAAS</p> Bantan T Milacic R Pihlar B Talanta 1998 47 929 941 10.1016/S0039-9140(98)00167-2 <p>Kinetics of the Release of Aluminum from Human Serum Dialuminum Transferrin to Citrate</p> Marques HM Journal of Inorganic Biochemistry 1991 41 187 193 10.1016/0162-0134(91)80011-6 2037846 <p>Speciation of aluminum in biological systems</p> Harris WR Berthon G Day JP Exley C Flaten TP Forbes WF Kiss T Orvig C Zatta PF Journal of Toxicology and Environmental Health 1996 48 543 568 10.1080/009841096161069 <p>Influence of chelating agents on the toxicity and distribution of beryllium in rats</p> Shukla S Sharma P Johri S Mathur R Journal of Applied Toxicology 1998 18 331 335 10.1002/(SICI)1099-1263(1998090)18:5<331::AID-JAT517>3.0.CO;2-0 9804433 <p>Protective effect of Tiron (4,5-dihydroxybenzene-1,3-disulfonic acid disodium salt) against beryllium-induced maternal and fetal toxicity in rats</p> Sharma P Shah ZA Shukla S Archives of Toxicology 2002 76 442 448 10.1007/s00204-002-0356-4 12185411